Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Opdivo | nivolumab | Bristol Myers Squibb | N-125554 RX | 2014-12-22 | 4 products |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Opdualag | nivolumab and relatlimab-rmbw | Bristol Myers Squibb | N-761234 RX | 2022-03-18 | 1 products |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Opdivo Qvantig | nivolumab and hyaluronidase-nvhy | Bristol Myers Squibb | N-761381 RX | 2024-12-27 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
opdivo | Biologic Licensing Application | 2025-06-30 |
opdivo qvantig | Biologic Licensing Application | 2025-06-06 |
opdualag | Biologic Licensing Application | 2024-03-01 |
Expiration | Code | ||
---|---|---|---|
nivolumab, Opdivo, Bristol-Myers Squibb Company | |||
2030-02-15 | Orphan excl. | ||
nivolumab / relatlimab, Opdualag, Bristol-Myers Squibb Company | |||
2029-03-18 | Orphan excl. |
Code | Description |
---|---|
J9299 | Injection, nivolumab, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 37 | 68 | 19 | 1 | 18 | 119 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 17 | 29 | 8 | 2 | 8 | 57 |
Lung neoplasms | D008175 | — | C34.90 | 11 | 19 | 7 | 1 | 11 | 44 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 3 | 3 | 2 | 2 | 4 | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 78 | 77 | 5 | — | 2 | 115 |
Melanoma | D008545 | — | — | 36 | 58 | 19 | — | 18 | 111 |
Colorectal neoplasms | D015179 | — | — | 24 | 29 | 3 | — | 1 | 42 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 12 | 20 | 3 | — | 5 | 36 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 13 | 22 | 1 | — | 1 | 32 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 15 | 16 | 4 | — | 1 | 28 |
Carcinoma | D002277 | — | C80.0 | 8 | 12 | 2 | — | 10 | 27 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 13 | 16 | 3 | — | 1 | 26 |
Adenocarcinoma | D000230 | — | — | 12 | 14 | 1 | — | 3 | 25 |
Urinary bladder neoplasms | D001749 | — | C67 | 9 | 14 | 3 | — | — | 24 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 17 | 19 | — | — | — | 26 |
Transitional cell carcinoma | D002295 | — | — | 10 | 11 | — | — | 2 | 19 |
Squamous cell carcinoma | D002294 | — | — | 3 | 10 | — | — | 5 | 17 |
Triple negative breast neoplasms | D064726 | — | — | 9 | 13 | — | — | — | 14 |
Urologic neoplasms | D014571 | — | C64-C68 | 7 | 9 | — | — | 1 | 13 |
Lymphoma | D008223 | — | C85.9 | 8 | 10 | — | — | 1 | 13 |
Colonic neoplasms | D003110 | — | C18 | 6 | 8 | — | — | — | 11 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 8 | 8 | — | — | — | 10 |
Malignant mesothelioma | D000086002 | — | — | 2 | 7 | — | — | 2 | 10 |
Sarcoma | D012509 | — | — | 3 | 7 | — | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gata2 deficiency | D000077428 | — | D46.22 | 2 | — | — | — | — | 2 |
Glandular and epithelial neoplasms | D009375 | — | — | 2 | — | — | — | — | 2 |
Myoepithelioma | D009208 | — | — | 2 | — | — | — | — | 2 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 1 | — | — | — | — | 1 |
Fallopian tube diseases | D005184 | EFO_0009548 | N83 | 1 | — | — | — | — | 1 |
Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
Neoplasms by histologic type | D009370 | — | — | 1 | — | — | — | — | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Long term adverse effects | D000069451 | — | — | — | — | — | — | 1 | 1 |
Encephalitis | D004660 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Nivolumab |
INN | nivolumab |
Description | Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, colon cancer, and liver cancer. It is used by slow injection into a vein.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >5GGQ:H|nivolumab heavy chain
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLF
LQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH
>5GGQ:L|nivolumab light chain
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP
EDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 5GGQ, 5GGR, 5WT9 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108738 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB09035 |
UNII ID | 31YO63LBSN (ChemIDplus, GSRS) |